Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Capital Expenditures (2020 - 2023)

BioAtla (BCAB) has 4 years of Capital Expenditures data on record, last reported at $8000.0 in Q4 2023.

  • For Q4 2023, Capital Expenditures changed N/A year-over-year to $8000.0; the TTM value through Sep 2024 reached $8000.0, down 91.11%, while the annual FY2023 figure was $98000.0, 9700.0% up from the prior year.
  • Capital Expenditures reached $8000.0 in Q4 2023 per BCAB's latest filing, down from $25000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $916000.0 in Q4 2021 and bottomed at -$728000.0 in Q3 2021.
  • Average Capital Expenditures over 4 years is $107533.3, with a median of $25000.0 recorded in 2023.
  • The widest YoY moves for Capital Expenditures: up 440.58% in 2021, down 746.51% in 2021.
  • A 4-year view of Capital Expenditures shows it stood at $590000.0 in 2020, then skyrocketed by 55.25% to $916000.0 in 2021, then crashed by 119.43% to -$178000.0 in 2022, then skyrocketed by 104.49% to $8000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $8000.0 in Q4 2023, $25000.0 in Q3 2023, and $15000.0 in Q2 2023.